Clinical Trial

Personalized Antisense Oligonucleotide Therapy for a Single Participant With PRPH2 Mutation Associated With Retinal Dystrophy

Name: Personalized Antisense Oligonucleotide Therapy for a Single Participant With PRPH2 Mutation Associated With Retinal Dystrophy — clinical trial record (NCT07177196)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with Retinal Dystrophy due to PRPH2 mutation

Trial Details

NCT Number	NCT07177196
Lead Sponsor	n-Lorem Foundation Collaborators: University of California, San Diego
Conditions	Retinal Dystrophy
Enrollment	1 participants
Start Date	2025-08-28
Primary Completion	2027-08 (estimated)
Study Completion	2027-08 (estimated)
Updated on ClinicalTrials.gov	2025-09-16